Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 847 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atrophy, Muscular Clear all
Recruiting No phase listed Observational

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

NCT03998202
View directory record Official record
Conditions
Colorectal Cancer, Sarcopenia
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
147
States / cities
Millville, Delaware • Newark, Delaware • Rehoboth Beach, Delaware + 114 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 9:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Efficacy of Protein Supplementation on Attenuating Muscle Atrophy Following Disuse in the Collegiate Population

NCT03454347
View directory record Official record
Conditions
Disuse Atrophy
Interventions
Profile Perform, Lower Limb Suspension
Dietary Supplement · Other
Lead sponsor
South Dakota State University
Other
Eligibility
18 Years to 25 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Brookings, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 22, 2026, 9:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Open-label Extension of the HOPE-2 Trial

NCT04428476
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Deramiocel (CAP-1002)
Biological
Lead sponsor
Capricor Inc.
Industry
Eligibility
10 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Sacramento, California • Aurora, Colorado • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 9:41 AM EDT
Recruiting Phase 1 Interventional

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

NCT07172971
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
SGLT-2 inhibitor, SGLT2 inhibitor
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 9:41 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Parent and Infant Inter(X)Action Intervention (PIXI)

NCT03836300
View directory record Official record
Conditions
Fragile X Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Dup15Q Syndrome, Duchenne Muscular Dystrophy, Phelan-McDermid Syndrome, Rett Syndrome, Smith Magenis Syndrome, Williams Syndrome, Turner Syndrome, Klinefelter Syndrome, Chromosome 22q11.2 Deletion Syndrome, Tuberous Sclerosis, Down Syndrome
Interventions
Parent-Infant Inter(X)action Intervention (PIXI)
Behavioral
Lead sponsor
RTI International
Other
Eligibility
Up to 99 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 9:41 AM EDT
Recruiting Phase 1 Interventional

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

NCT06555419
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Nusinersen, ThecaFlex DRx System
Drug · Device
Lead sponsor
Biogen
Industry
Eligibility
3 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 22, 2026, 9:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Extracellular RNA Biomarkers of Myotonic Dystrophy

NCT05020002
View directory record Official record
Conditions
Myotonic Dystrophy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years and older
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 22, 2026, 9:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bingocize: A Novel Mobile Application for Older Adult Health

NCT03629912
View directory record Official record
Conditions
Activities of Daily Living, Accidental Fall, Sarcopenia, Arteriosclerosis, Diabetes Mellitus, Type 2, Hypertension, Cognitive Decline, Executive Function, Cognitive Aging
Interventions
Socially-Based Exercise Intervention for Older Adults
Behavioral
Lead sponsor
Western Kentucky University
Other
Eligibility
60 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
4
States / cities
Dixon, Kentucky • Henderson, Tennessee • Johnson City, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 22, 2026, 9:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of 16 Weeks of Hip Adduction and Abduction Resistance Exercise

NCT01228877
View directory record Official record
Conditions
Osteoporosis, Osteopenia, Sarcopenia
Interventions
exercise
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
25 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 22, 2026, 9:41 AM EDT
Completed Not applicable Interventional Results available

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

NCT04675775
View directory record Official record
Conditions
Cirrhosis, Ascites, Liver Diseases, Frailty, Sarcopenia, Hepatic Encephalopathy
Interventions
Medically-tailored meals (MTM), Protein supplements, Nutrition education handout
Other · Dietary Supplement · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 22, 2026, 9:41 AM EDT
Not listed Not applicable Interventional

Effects of a Weight Based Training Program on MS Patients

NCT04002492
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Bodyweight training
Behavioral
Lead sponsor
Holy Name Medical Center, Inc.
Other
Eligibility
40 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 22, 2026, 9:41 AM EDT
Recruiting Phase 2 Interventional

Vasodilator and Exercise Study for DMD (VASO-REx)

NCT06290713
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy, Muscular Dystrophy in Children, Vasodilation, Exercise, DMD
Interventions
Tadalafil, Placebo, Exercise Training
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
6 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 9:41 AM EDT
Active, not recruiting No phase listed Observational

AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD

NCT05683379
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
AAV8 DetectCDx
Diagnostic Test
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
0 Years to 25 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 9:41 AM EDT
Recruiting No phase listed Observational

DMD Voice: Qualitative Interviews With Patients and Caregivers

NCT06925269
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
Not listed
Lead sponsor
Red Nucleus Enterprise Solutions, LLC
Industry
Eligibility
10 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Yardley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 22, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

NCT03452488
View directory record Official record
Conditions
Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
Interventions
BIO101, Placebo
Drug
Lead sponsor
Biophytis
Industry
Eligibility
65 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
19
States / cities
Banning, California • Garden Grove, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 22, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty

NCT05283486
View directory record Official record
Conditions
Sarcopenia, Frailty, Aging
Interventions
MYMD-1 600MG, MYMD-1 750mg, MYMD-1 900mg, MYMD-1 1050mg, placebo 600mg, placebo 750mg, placebo 900mg, placebo 1050mg
Drug
Lead sponsor
TNF Pharmaceuticals, Inc.
Industry
Eligibility
65 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Clearwater, Florida • Tampa, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 22, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of FDY-5301 in Major Trauma Patients in ICU

NCT04430283
View directory record Official record
Conditions
ICU Acquired Weakness
Interventions
FDY-5301, Placebo
Drug · Other
Lead sponsor
Faraday Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 22, 2026, 9:41 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

NCT05517603
View directory record Official record
Conditions
Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
Interventions
AJ201, Placebo
Drug
Lead sponsor
AnnJi Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Orange, California • Palo Alto, California • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 22, 2026, 9:41 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

NCT05397470
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
Losmapimod, Placebo oral tablet
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 22, 2026, 9:41 AM EDT
Terminated Phase 1 Interventional

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

NCT04184882
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
Bocidelpar, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
8 Years to 16 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Sacramento, California • Kansas City, Kansas • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 22, 2026, 9:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nutritional and Contractile Regulation of Muscle Growth

NCT00891696
View directory record Official record
Conditions
Sarcopenia
Interventions
Rapamycin, Amino acid supplementation, Low-intensity resistance exercise, Sodium nitroprusside, Blood flow restriction cuff
Drug · Other · Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 22, 2026, 9:41 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

NCT07221669
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Salanersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
0 Days to 42 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Chicago, Illinois • Flower Mound, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 9:41 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Screening for Age-Related Skeletal Muscle Dysfunction

NCT02277236
View directory record Official record
Conditions
Sarcopenia
Interventions
DXA scanning, CT imaging
Radiation
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
45 Years to 85 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 22, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Effect of Neuromuscular Electrical Stimulation (NMES)

NCT00765739
View directory record Official record
Conditions
Muscle Fiber Atrophy, Type II
Interventions
Neuromuscular electrical stimulation, voluntary strengthening exercise
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 22, 2026, 9:41 AM EDT